论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
miR-218 过表达通过靶向 Runx2 使 PTEN/PI3K/AKT 通路失活以抑制乳头状甲状腺癌的发生
Authors Han M, Chen L, Wang Y
Received 24 April 2018
Accepted for publication 14 July 2018
Published 28 September 2018 Volume 2018:11 Pages 6305—6316
DOI https://doi.org/10.2147/OTT.S172152
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Colin Mak
Peer reviewer comments 3
Editor who approved publication: Dr Yao Dai
Background: It was previously reported that downregulation of miR-218 promoted thyroid cancer cell invasion, migration, and proliferation. However, the biological functions of miR-218 and its possible regulatory mechanisms in papillary thyroid cancer (PTC) cells are still elusive.
Materials and methods: The expression levels of miR-218 and Runx2 in PTC tissues and cells were determined by quantitative real-time PCR (qRT-PCR) and Western blot. The effects of miR-218 overexpression on cell viability, invasion, apoptosis, and PTEN/PI3K/AKT pathway in PTC cells were evaluated by cell counting kit-8 assay, Transwell invasion assay, flow cytometry assay, and Western blot, respectively. Luciferase reporter assay and qRT-PCR were performed to identify the target of miR-218 . Xenograft tumor experiment was performed to confirm the biological roles of miR-218 and its potential mechanisms in vivo.
Results: miR-218 expression was downregulated and Runx2 expression was upregulated in PTC tissues and cells. Overexpression of miR-218 suppressed viability and invasion, and induced apoptosis of PTC cells in vitro, while Runx2 overexpression greatly abolished these effects. miR-218 overexpression inactivated the PTEN/PI3K/AKT pathway, which was abated by Runx2 upregulation. Additionally, Runx2 was validated to be a direct target of miR-218 . Moreover, enforced expression of miR-218 inhibited tumor growth and Runx2 expression, and blocked PTEN/PI3K/AKT pathway in vivo.
Conclusion: miR-218 overexpression suppresses the tumorigenesis of PTC via downregulating PTEN/PI3K/AKT pathway by targeting Runx2, which indicates that miR-218 may be a potential therapeutic target for human PTC.
Keywords: miR-218 , papillary thyroid cancer, PTEN/PI3K/AKT, Runx2